Physician profile
Tracy E Levine
NPI 1972608818
$1,167.28
in general payments reported to CMS, 2019-2025
24 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $197 · 2021: $40.87 · 2022: $135 · 2023: $126 · 2024: $175 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $128.56 | 2019-2021 | |
| Sage Therapeutics, LLC | $127.63 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $92.38 | 2019-2022 | |
| Exact Sciences Corporation | $72.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Exeltis, USA INC. | $69.91 | 2019-2024 | Slynd |
| Pfizer INC. | $65.67 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $55.91 | 2019-2020 | |
| Astellas Pharma US INC | $55.30 | 2019-2025 | Veozah |
| Minerva Surgical, INC | $52.22 | 2022 | |
| Sumitomo Pharma America, INC. | $50.09 | 2023-2024 | Myfembree |
| Duchesnay USA Incorporated | $44.21 | 2019-2020 | |
| Organon LLC | $43.93 | 2022-2024 | |
| Myovant Sciences INC. | $41.64 | 2022 | |
| Lupin INC. | $36.13 | 2020 | |
| Mayne Pharma Commercial LLC | $32.22 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $31.09 | 2019-2024 | Paragard T 380a |
| Alexion Pharmaceuticals, INC. | $30.11 | 2019 | |
| Glaxosmithkline, LLC. | $25.45 | 2025 | Nucala |
| Supernus Pharmaceuticals, INC. | $23.99 | 2025 | Qelbree |
| Medtronic, INC. | $21.67 | 2025 | Closurefast |
| Daiichi Sankyo INC. | $21.52 | 2023 | Injectafer |
| Millicent US INC | $17.13 | 2019 | |
| Mission Pharmacal Company | $17.10 | 2020 | |
| Mylan Pharmaceuticals INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.